Hyun-Sang Cho

Hyun-Sang Cho

Auto-generated profile, based on publicly available information

Hyun-Sang Cho

Yonsei University College of Medicine

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 February 2007 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
EPEdward B. Perry
Edward B. Perry
JCJoyce A. Cramer
Joyce A. Cramer
HCHyun-Sang Cho
Hyun-Sang Cho
IPIsmene L. Petrakis
Ismene L. Petrakis
LKLaurence P. Karper
Laurence P. Karper
YGYale Ketamine Study Group
Yale Ketamine Study Group

1 November 2009 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
EKEosu Kim
Eosu Kim
YJYoung-Chul Jung
Young-Chul Jung
JKJeonghun Ku
Jeonghun Ku
Jae-Jin KimJae-Jin Kim
Jae-Jin Kim
HLHyeongrae Lee
Hyeongrae Lee
HCHyun-Sang Cho
Hyun-Sang Cho

13 May 2013 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
DRDaeyoung Roh
Daeyoung Roh
JCJhin-Goo Chang
Jhin-Goo Chang
CKChan-Hyung Kim
Chan-Hyung Kim
HCHyun-Sang Cho
Hyun-Sang Cho
SASuk Kyoon An
Suk Kyoon An
YJYoung-Chul Jung
Young-Chul Jung
Objective: The co-prescription of multiple antipsychotic drugs continues to increase despite a lack of evidence supporting this practice. The purpose of this study was to quantify and describe recent trends of antipsychotic polypharmacy in Korean schizophrenic inpatients by comparing prescribed medications between the years of 2005 and 2010. Methods: We reviewed comprehensive medication profiles of schizophrenic patients discharged from a university psychiatric hospital in 2005 ( n =194) or 2010 ( n =201). Antipsychotic polypharmacy was defined as the concurrent receipt of two or more chemically distinct antipsychotics for at least 14 days. High antipsychotic dose was defined as a prescribed daily dose to defined daily dose ratio of greater than 1.5. Results: Antipsychotic polypharmacy increased between 2005 (37.1%) and 2010 (48.3%, p =0.025). The most frequently used drug within combinations of antipsychotics was haloperidol in 2005 (51.4%) and quetiapine in 2010 (48.5%). Overall, no changes were observed between 2005 and 2010 in the rate of prescribing high-dose antipsychotics. High-dose antipsychotic monotherapy decreased across years (from 30.4 to 18.4%), but high-dose antipsychotic polypharmacy increased (from 34.0 to 45.3%). Regression analysis revealed that antipsychotic polypharmacy was strongly associated with high doses of prescribed antipsychotics (odds ratio=18.60, p <0.001). Conclusions: The practice of prescribing multiple antipsychotics to patients with schizophrenia is increasing, and high-dose antipsychotic drugs are more likely to be prescribed in combination than in isolation. The reasons for this pattern of prescription and its impact warrants further study.

1 April 2008 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
EKEosu Kim
Eosu Kim
DPDong-Wha Park
Dong-Wha Park
SCSong-Hee Choi
Song-Hee Choi
Jae-Jin KimJae-Jin Kim
Jae-Jin Kim
HCHyun-Sang Cho
Hyun-Sang Cho
Weight gain and other metabolic disturbances have now become discouraging, major side effects of atypical antipsychotic drugs (AAPDs). The novel strategies required to counteract these serious consequences, however, should avoid modulating the activities of the neurotransmitter receptors involved because those receptors are the therapeutic targets of AAPDs. Adenosine monophosphate-activated protein kinase is an enzyme that plays a pivotal role in energy homeostasis. We hypothesized that α-lipoic acid (ALA), which is known to modulate adenosine monophosphate-activated protein kinase activity in the hypothalamus and peripheral tissues, would ameliorate AAPD-induced weight gain. We describe the case series of a 12-week ALA trial in schizophrenia patients treated with AAPDs. Two of 7 enrolled subjects were dropped from the study because of noncompliance and demand for new medication to treat depressive symptoms, respectively. The mean (SD) weight loss was 3.16 (3.20) kg (P = 0.043, last observation carried forward; median, 3.03 kg; range, 0-8.85 kg). On average, body mass index showed a significant reduction (P = 0.028) over the 12 weeks. During the same period, a statistically significant reduction was also observed in total cholesterol levels (P = 0.042), and there was a weak trend toward the reduction in insulin resistance (homeostasis model assessment of insulin resistance) (P = 0.080). Three subjects reported increased energy subjectively. The total scores on the Brief Psychiatric Rating Scale and the Montgomery-Asberg Depression Rating Scale did not vary significantly during the study. These preliminary data suggest the possibility that ALA can ameliorate the adverse metabolic effects induced by AAPDs. To confirm the benefits of ALA, more extended study is warranted.

12 June 2013 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
TKTae Yong Kim
Tae Yong Kim
HCHae Gyung Chung
Hae Gyung Chung
HSHan-Sang Shin
Han-Sang Shin
SKSe Joo Kim
Se Joo Kim
JCJin Hee Choi
Jin Hee Choi
HCHyun-Sang Cho
Hyun-Sang Cho
Background The symptomatology of posttraumatic stress disorder (PTSD) is related not only to the intensity of the causative trauma, but also to alcohol use and genetic factors. Among the many candidate genes, the apolipoprotein E gene (APOE) is thought to be associated with stress reactivity. Methods Korean veterans of the Vietnam War with (n = 128) or without (n = 128) PTSD participated in this study. The Clinician-Administered PTSD Scale and Combat Exposure Scale were administered, and the severity of alcohol use was assessed among these veterans. The APOE polymorphism and clinical variables of the subjects were compared, and associations between PTSD and potential explanatory variables were tested using logistic regression analysis. Results Higher frequencies of APOE ε2 alleles and a greater number of individuals with the ε2 allele were found in the PTSD group. Among patients with PTSD, ε2-allele noncarriers consumed alcohol in greater amounts and more frequently than did ε2-allele carriers. Regression analysis revealed a significant interactional effect between harmful drinking and the absence of the ε2 allele associated with PTSD risk. Conclusions These results suggest that the APOE ε2 allele operates as a susceptibility gene for combat-related PTSD, with the relationship between alcohol use and PTSD differing according to the ε2-allele status. Future studies should determine the role of the APOE in adaptation to extreme stress, the development of PTSD, and comorbid alcohol-related disorders.